FindTrial
Sign In

Gene testing in triple negative breast cancer at two points: before and after chemotherapy

Paired targeted genomic profiling of triple negative breast cancer to understand the mechanisms of chemoresistance and develop novel treatment targets

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/05/042779
Enrollment
100
Registered
2022-05-24
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50- Malignant neoplasm of breast

Interventions

None listed

Sponsors

ICMR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with triple negative breast cancer Non metastatic disease Planned for neoadjuvant chemotherapy Willing to participate in study

Exclusion criteria

Exclusion criteria: Patients with prior history of cancer Patients planned for upfront surgery

Design outcomes

Primary

MeasureTime frame
Identification of targetable mutations in residual disease in triple negative breast cancer that were not initially present in the tumor cells and in germlineTimepoint: Six months—

Secondary

MeasureTime frame
Identifying the associations between differential mutations with disease-free survival of patients with triple negative breast cancer Identification of genetic mutations associated with incomplete response to chemotherapy Identification of new mutations that develop in recurrent disease Timepoint: Six months—

Countries

India

Contacts

Public ContactAtul Batr

AIIMS

batraatul85@gmail.com01129575043

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026